ShareCompartir
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail.
Appendix D: Routine Follow-Up After Contraceptive Initiation
These recommendations address when routine follow-up is recommended for safe and effective continued use of contraception for healthy women. The recommendations refer to general situations and might vary for different users and different situations. Specific populations that might benefit from more frequent follow-up visits include adolescents, those with certain medical conditions or characteristics, and those with multiple medical conditions.
|
TABLE. Routine follow-up after contraceptive initiation |
|||||
|---|---|---|---|---|---|
|
Action |
Contraceptive method |
||||
|
Cu-IUD or LNG-IUD |
Implant |
Injectable |
CHC |
POP |
|
|
General follow-up |
|||||
|
Advise women to return at any time to discuss side effects or other problems or if they want to change the method. Advise women using IUDs, implants, or injectables when the IUD or implant needs to be removed or when a reinjection is needed. No routine follow-up visit is required. |
X |
X |
X |
X |
X |
|
Other routine visits |
|||||
|
Assess the woman's satisfaction with her current method and whether she has any concerns about method use. |
X |
X |
X |
X |
X |
|
Assess any changes in health status, including medications, that would change the method's appropriateness for safe and effective continued use based on U.S. MEC (i.e., category 3 and 4 conditions and characteristics) (Box 2). |
X |
X |
X |
X |
X |
|
Consider performing an examination to check for the presence of IUD strings. |
X |
— |
— |
— |
— |
|
Consider assessing weight changes and counseling women who are concerned about weight change perceived to be associated with their contraceptive method. |
X |
X |
X |
X |
X |
|
Measure blood pressure. |
— |
— |
— |
X |
— |
|
Abbreviations: CHC = combined hormonal contraceptive; Cu-IUD = copper-containing intrauterine device; HIV = human immunodeficiency virus; IUD = intrauterine device; LNG-IUD = levonorgestrel-releasing intrauterine device; POP = progestin-only pill; U.S. MEC = U.S. Medical Eligibility Criteria for Contraceptive Use, 2010. |
|||||
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.
All MMWR HTML versions of articles are electronic conversions from typeset documents. This conversion might result in character translation or format errors in the HTML version.
Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371;
telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.
